Merck KGaA (OTCMKTS:MKGAY) Rating Increased to Buy at Bank of America

Merck KGaA (OTCMKTS:MKGAYGet Rating) was upgraded by analysts at Bank of America from a “neutral” rating to a “buy” rating in a research note issued on Monday, The Fly reports.

Separately, Jefferies Financial Group began coverage on shares of Merck KGaA in a research report on Monday, July 25th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $252.50.

Merck KGaA Price Performance

MKGAY opened at $38.36 on Monday. Merck KGaA has a fifty-two week low of $32.53 and a fifty-two week high of $42.02. The firm has a 50 day simple moving average of $38.36 and a 200 day simple moving average of $38.36.

About Merck KGaA

(Get Rating)

Merck KGaA is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It operates through the following sectors: Healthcare, Life Science, Performance Materials and Corporate and Other. The Healthcare sector discovers, develops, and produces prescription medicines used to treat cancer, multiple sclerosis, and infertility.

Recommended Stories

The Fly logo

Analyst Recommendations for Merck KGaA (OTCMKTS:MKGAY)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.